We propose to continue our multidisciplinary research program which will integrate substantial institutional expertise in infectious diseases, neurology, immunology, retrovirology and herpes viruses, parasitology, agents active against these agents, and numerous clinical resources in both South Carolina and North Carolina focusing on the evaluation of novel therapies for HIV-infected persons. A group of clinical investigators at UNC as well as 4 satellite units in Charlotte, Greensboro, Raleigh and Charleston, South Carolina will collectively study new compounds active against HIV and associated diseases in 150 new patients and 277 previously enrolled patients in a timely and cost-effective manner. We shall continue our high rate of accrual among minorities, women and IVDUs. Trials will be of all phases (I, II, III) and types (primary infection, opportunistic infection, neurology, malignancy). Patients will be followed for in vivo evidence of study drug effects on HIV, EBV, CMV, HSV and other opportunistic infections using our core virology laboratory. Pharmacokinetics will be monitored in our General Clinical Research Center. Concepts for new protocols will originate with the investigators, through participation in ACTG committees and the newly established scientific advisory board. Outreach to the community and local physicians will be accomplished through our community advisory boards at each site, our statewide newsletter, and continuing education lectures around the state. Links will continue with 5 other major NIH-funded clinical research grants and 4 different NIH training grants.

Project Start
1997-01-01
Project End
1997-12-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
11
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9
Thio, Chloe L; Smeaton, Laura; Hollabaugh, Kimberly et al. (2015) Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks. AIDS 29:1173-82
Smith, Kimberly Y; Tierney, Camlin; Mollan, Katie et al. (2014) Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis 58:555-63
Kempen, John H; Sugar, Elizabeth A; Varma, Rohit et al. (2014) Risk of cataract among subjects with acquired immune deficiency syndrome free of ocular opportunistic infections. Ophthalmology 121:2317-24
Kozak, Igor; Vaidya, Vijay; Van Natta, Mark L et al. (2014) The prevalence and incidence of epiretinal membranes in eyes with inactive extramacular CMV retinitis. Invest Ophthalmol Vis Sci 55:4304-12
Venuto, Charles S; Mollan, Katie; Ma, Qing et al. (2014) Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. J Antimicrob Chemother 69:3300-10

Showing the most recent 10 out of 174 publications